Identification
- Summary
-
Hemoglobinis an iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
- Generic Name
- Hemoglobin
- DrugBank Accession Number
- DB04945
- Background
-
The respiratory protein of the red blood cells. It consists primarily of globin and heme.
- Type
- Biotech
- Groups
- Approved, Experimental, Investigational
- Biologic Classification
-
Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- 蛋白质的平均重量t
- Not Available
- Sequences
- Not Available
- Synonyms
-
- Deoxyhemoglobin
- Haemoglobin
- Human hemoglobin
Pharmacology
- Indication
-
Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hemorrhage.
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
-
A heme group is made up of iron (Fe) ion (charged atom) located in a heterocyclic ring, which is also called a porphyrin ring. The site of oxygen binding, the iron ion, binds with the nitrogens located in the center of the porphyrin ring. The iron ion binds with high affinity to the globular protein through the imidazole ring of the F8 residue on histidine which is found below the porphyrin ring. A sixth position can bind reversibly to oxygen, completing the formation of the octahedral group. One oxygen atom binds Fe and the other is found to protrude at an angle. When oxygen is not bound to Fe, a water molecule (weakly bound) fills the site, producing a distorted shape, often described as an octahedron.
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
This means that the oxygen binding curve for fetal hemoglobin is left-shifted (i.e., a higher percentage of hemoglobin has oxygen bound to it at lower oxygen tension), in comparison to that of adult hemoglobin
- Metabolism
-
There is a group of genetic disorders, known as the porphyrias that are characterized by errors in metabolic pathways of heme synthesis
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Over the Counter Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Deschiens Sirop Liquid 8.3 g / 100 mL Oral Rodeca Inc., Division Of Technilab Inc. 1951-12-31 1999-09-17 Canada 
Categories
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- VSU9IB86SP
- CAS number
- 9008-02-0
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 2 Completed Treatment Acute Coronary Syndrome (ACS)/Coronary Occlusions 1 2 Completed Treatment Angina Pectoris/Myocardial Infarction/Unstable Angina Pectoris 1 2 Completed Treatment Lactic Acidosis/Shock, Hemorrhagic/Traumatic Shock 1 2 Unknown Status Treatment Coronary Artery Disease (CAD) 1 2 Unknown Status Treatment Wounds and Injuries 1 2 Withdrawn Treatment Lactic Acidosis/Shock, Hemorrhagic/Traumas 1 Not Available Completed Not Available Adult Solid Tumor/Anaemia deficiencies 1 Not Available Completed Not Available Elective Hepatic Resection 1 Not Available Completed Not Available Patients' Assessment 1 Not Available Unknown Status Not Available Renal Insufficiency, Acute 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Liquid Oral 8.3 g / 100 mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52